Quantum Genesis AI Corp. (OTC: QGAI) issued a statement on May 19, 2026, to clarify the distinction between the company and Quantumzyme LLP, a separate entity based in Bengaluru, India, following confusion arising from prior press releases that referenced scientific publications in the enzyme engineering field. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate of Quantum Genesis AI.
The clarification comes after press releases dated November 5, 2025, and February 12, 2026, cited research publications that identified Quantumzyme LLP and reflected the affiliations of contributing researchers. Quantum Genesis AI now seeks to provide additional context regarding the intellectual property and technology rights previously transferred to the company pursuant to an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment filed on April 29, 2026.
According to the company, scientific publications arising from research activities undertaken by its Chief Executive Officer, Naveen Kulkarni, appropriately reflect the affiliations of the researchers at the time the work was conducted. However, the company believes that the Asset Purchase Agreement transferred underlying technology, methodologies, computational approaches, know-how, and related intellectual property associated with its core enzyme engineering and biocatalysis business. As a result, to the extent research activities conducted by Mr. Kulkarni—whether directly or through Quantumzyme LLP—relate to the company’s field and are based on or derived from the transferred technology platform, the company asserts that such intellectual property falls within the scope of rights transferred to it.
This announcement is significant for investors and industry observers because it clarifies the ownership of key intellectual property that underpins Quantum Genesis AI’s business. The company’s focus on enzyme engineering, molecular modeling, and biocatalysis relies on proprietary technology and know-how. By distinguishing its assets from those of Quantumzyme LLP, the company aims to prevent potential confusion about the source of its innovations and to reinforce its control over critical research outputs.
For stakeholders, the clarification may impact perceptions of the company’s value and its ability to commercialize its technology. The company’s prior disclosures regarding scientific publications were made based on its ownership of the relevant intellectual property, and this statement serves to reaffirm that position. The company also reiterated its commitment to transparency and responsible corporate governance.
Quantum Genesis AI Corp. is a biotechnology company focused on advancing next-generation technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. Its strategy includes leveraging data-driven tools to support research and technology development across emerging sectors.
For more information, visit qgaicorp.com or the company’s profile at otcmarkets.com/stock/QGAI.
